GlaxoSmithKline Pharmaceuticals
- Market Cap
- ₹46,207 Cr
- P/E
- 40.30
Key Fundamentals
MidcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 61.40%
- Debt to Equity
- 0.02
- EPS (TTM)
- ₹67.68
- Book Value
- ₹111.04
- Market Cap
- ₹46,207 Cr
- P/E (TTM)
- 40.30
- P/B
- 24.56
- ROE
- 45.60%
- Dividend Yield
- 2.10%
- EBITDA
- ₹1,455 Cr
- 52W High
- ₹3,120.70
- 52W Low
- ₹2,088.10
- Day Range
- ₹2,680.00 – ₹2,748.00
- Volume
- 84,480
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| 2,727.60 | 40.30 | 46,207 | 24.56 | 2.16% | 45.60% | 61.40% | 4,159 | 1,147 | |
| Median 8 companies | 2,089.75 | 41.35 | 1,21,840 | 7.39 | 0.70% | 17.40% | 19.15% | 22,770 | 2,808 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 77
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 58
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 30
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 84
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 34
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 54
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
- Company has been maintaining a healthy dividend payout of 94.6%
Weaknesses
2- Stock is trading at 24.6 times its book value
- The company has delivered a poor sales growth of 5.49% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 5 | 12 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Neutral
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 59.61
- Neutral
- MACD (12,26,9)
- 25.58
- Bullish
- SMA (50)
- 2,657.15
- Bullish
- SMA (200)
- 2,533.22
- Bullish
As of
Analyst Rating
3 of 4 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +3.02% |
|---|---|
| 5Y | +5.49% |
| 3Y | +5.53% |
| 1Y | +1.95% |
| TTM | +12.14% |
Net profit
| 10Y | +10.67% |
|---|---|
| 5Y | +23.68% |
| 3Y | +19.24% |
| 1Y | +11.64% |
| TTM | +20.10% |
Operating cash flow
| 10Y | +20.58% |
|---|---|
| 5Y | +9.33% |
| 3Y | +23.11% |
| 1Y | −30.00% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +17.41 pp |
|---|---|
| 5Y | +13.81 pp |
| 3Y | +9.53 pp |
| 1Y | +2.80 pp |
| TTM | +1.46 pp |
Revenue by year
| Mar 2017 | ₹2,908 Cr |
|---|---|
| Mar 2018 | ₹2,871 Cr |
| Mar 2019 | ₹3,128 Cr |
| Mar 2020 | ₹3,224 Cr |
| Mar 2021 | ₹2,926 Cr |
| Mar 2022 | ₹3,278 Cr |
| Mar 2023 | ₹3,252 Cr |
| Mar 2024 | ₹3,454 Cr |
| Mar 2025 | ₹3,749 Cr |
| Mar 2026 | ₹3,822 Cr |
Net profit by year
| Mar 2017 | ₹337 Cr |
|---|---|
| Mar 2018 | ₹351 Cr |
| Mar 2019 | ₹445 Cr |
| Mar 2020 | ₹93.00 Cr |
| Mar 2021 | ₹358 Cr |
| Mar 2022 | ₹1,695 Cr |
| Mar 2023 | ₹611 Cr |
| Mar 2024 | ₹590 Cr |
| Mar 2025 | ₹928 Cr |
| Mar 2026 | ₹1,036 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
As of 2026-11-16, GlaxoSmithKline Pharmaceuticals Ltd trades at ₹2,651.7 with a market cap of ₹44,921.4 crore, commanding a TTM P/E of 39.18x and P/B of 23.88x. The company operates as a virtually debt-free entity with a ROE of 45.69% and ROCE of 55.36%, though its five-year revenue CAGR of 5% reflects modest topline expansion relative to its premium valuation.
- Exceptional return on equity of 45.69% as of 2026-11-16, with a three-year average ROE of 43.5%, indicating highly efficient capital deployment relative to pharma peers.
- Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.01, providing significant financial resilience and flexibility for future investments.
- ROCE of 55.36% signals that the company generates substantial returns on total capital employed, reflecting strong pricing power and operational efficiency.
- TTM profit growth of 19% and a three-year compounded profit growth of 18% demonstrate accelerating earnings momentum, outpacing the 10-year profit CAGR of 10%.
- Healthy dividend yield of 2.13% supported by a payout ratio of 94.6%, offering consistent cash returns to shareholders.
- TTM sales growth has accelerated to 12%, a meaningful improvement over the five-year compounded sales growth of 5%, suggesting improving demand or product mix.
- The stock trades roughly 15% below its 52-week high of ₹3,120.7, having recovered significantly from its 52-week low of ₹2,088.1, reflecting a price correction from peak levels.
- Ten-year ROE averaging 33% underscores a long track record of consistently high profitability through multiple market cycles.
- Five-year compounded sales growth of just 5% indicates structurally slow topline expansion for a company commanding a P/E of 39.18x.
- TTM P/E of 39.18x is a significant premium to broader market and sector averages, embedding high growth expectations into the current price.
- Ten-year compounded revenue growth of only 3% raises questions about the company's ability to sustain meaningful topline acceleration over extended periods.
- A dividend payout ratio of 94.6%, while rewarding shareholders, leaves very limited retained earnings for organic reinvestment, R&D, or new product launches.
- The stock's 10-year price CAGR of 7% has lagged its profit growth CAGR of 10% over the same period, suggesting the market has periodically de-rated the stock.
- Five-year stock price CAGR of 10% and one-year return of 6% indicate modest capital appreciation relative to the high valuation multiples the stock commands.
- Despite TTM sales growth accelerating to 12%, the gap between the 10-year sales CAGR of 3% and 10-year profit CAGR of 10% suggests earnings growth has leaned on margin expansion, which may have limited further room.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: GSK Pharma delivered a strong Q2FY27 with 31% profit growth and 21% revenue expansion, signaling healthy operational momentum. No material headwinds emerged in the recent news cycle. The ₹630 crore RPT with GSK Biological is routine parent-subsidiary business. If the double-digit top-line growth sustains, the earnings trajectory remains firmly positive heading into H2FY27.
- Q2FY27 profit jumps 31% YoY Nov 3
Standalone net profit rose 31% YoY to ₹334.6 crore in Q2FY27. Revenue from operations grew 21% YoY to ₹1,179.9 crore.
- ₹630 crore RPT approval sought Nov 17
GSK Pharma seeks shareholder approval for related party transactions up to ₹630 crore with GSK Biological S.A. for FY27.
- Analyst meet held Nov 4 Oct 28
GSK Pharma hosted a digital analyst and institutional investor meeting on November 4, 2026, with the video recording uploaded on November 5.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 | 1,184 |
| Expenses | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 | 643 | 782 |
| Operating Profit | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 | 296 | 402 |
| OPM % | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% | 31% | 34% |
| Other Income | 28 | 28.11 | 29.83 | 36 | 34.54 | 35 | 41 | 44 | 33.57 | 50 | 36 | 44 | 72.78 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0.49 |
| Depreciation | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 | 15.02 |
| Exceptional Items | — | −163 | 2.4 | — | 4.69 | — | — | — | 2.64 | — | — | — | — |
| PBT | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 | 459 |
| Tax % | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% | 26% | 27% |
| Net Profit | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 | 336 |
| EPS (₹) | 12.84 | 2.70 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 | 15.20 | 17.45 | 16.40 | 14.00 | 19.83 |
| YoY Sales growth | 4 | 0 | 18 | 7 | 6 | 18 | 5 | −1 | −3 | 10 | 2 | 17 | 21 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,305 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 | 4,159 |
| Expenses | 2,672 | 2,360 | 2,489 | 2,363 | 2,527 | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,570 | 2,512 | 2,739 |
| Operating Profit | 633 | 478 | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 909 | 1,179 | 1,309 | 1,420 |
| OPM % | 19% | 17% | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 26% | 31% | 34% | 34% |
| Other Income | 149 | 125 | 119 | 70 | 102 | 79.01 | 9 | 1,401 | 101 | 123 | 149 | 145 | 203 |
| Interest | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 | 1 | 3 | 3 |
| Depreciation | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 70 | 67 | 66 | 64 |
| Exceptional Items | — | — | — | — | 28.69 | −341 | — | — | — | −144 | — | 20.62 | — |
| PBT | 756 | 578 | 511 | 540 | 683 | 306 | 525 | 2,093 | 836 | 816 | 1,260 | 1,406 | 1,555 |
| Tax % | 37% | 35% | 34% | 35% | 35% | 70% | 32% | 19% | 27% | 28% | 26% | 26% | — |
| Net Profit | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 1,036 | 1,147 |
| EPS (₹) | 28.12 | 22.20 | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 54.75 | 61.15 | 67.68 |
| Div. Payout % | 111% | 113% | 75% | 85% | 76% | 727% | 142% | 90% | 89% | 92% | 99% | 93% | — |
| Sales growth | 29 | −14 | 2 | −1 | 9 | 3 | −9 | 12 | −1 | 6 | 9 | 2 | 12 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 | 2,098 | 1,712 |
| Borrowings | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 19 | 10 | 33 | 39 |
| Other Liabilities | 1,384 | 869 | 995 | 1,889 | 1,771 | 1,315 | 1,602 | 1,950 | 1,570 | 1,760 | 2,147 | 2,023 | 2,048 |
| Total Liabilities | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 | 3,969 |
| Fixed Assets | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 | 281 | 293 |
| CWIP | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 14 | 14 | 33 | 35 |
| Investments | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 | 1,392 | 1,525 |
| Other Assets | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 | 2,618 | 2,116 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 | 3,969 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 338 | 139 | 234 | 473 | 409 | 490 | 578 | 811 | 484 | 582 | 1,290 | 903 |
| Investing | 180 | 499 | 301 | −104 | −153 | −57 | 418 | −406 | 808 | 9 | −46 | 397 |
| Financing | −497 | −638 | −511 | −307 | −358 | −428 | −696 | −524 | −1,543 | −562 | −769 | −737 |
| Net Cash Flow | 21 | 0 | 24 | 62 | −102 | 6 | 300 | −119 | −251 | 29 | 475 | 563 |
| Free Cash Flow | 175 | −69 | −24 | 639 | 166 | 336 | 536 | 2,371 | 451 | 573 | 1,273 | 870 |
| CFO/EBITDA | 93 | 72 | 94 | 133 | 101 | 103 | 121 | 122 | 93 | 92 | 116 | 93 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 11 | 16 | 21 | 19 | 14 | 11 | 27 | 23 | 22 | 23 | 28 | 26 |
| Inventory Days | 91 | 156 | 111 | 147 | 131 | 135 | 159 | 144 | 131 | 144 | 126 | 124 |
| Days Payable | 74 | 97 | 73 | 149 | 109 | 100 | 135 | 156 | 122 | 171 | 186 | 154 |
| Cash Conversion Cycle | 27 | 75 | 60 | 17 | 36 | 46 | 50 | 11 | 31 | −4 | −31 | −4 |
| Working Capital Days | −48 | 26 | 7 | −90 | −72 | −38 | −39 | −94 | −57 | −64 | −99 | −91 |
| ROCE % | 42% | 29% | 22% | 26% | 31% | 33% | 38% | 37% | 36% | 51% | 63% | 61% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view GlaxoSmithKline Pharmaceuticals insights
66 extracted metrics across FY14–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT
- Q4 FY26 concall · Jun 2026Transcript PPT
- Q4 FY26 concall · May 2026PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- 3 Aug 2026
- 13 May 2026
- 6 Nov 2025
- General announcements 8 Nov 2026
- General announcements 5 Nov 2026
Frequently Asked Questions about GlaxoSmithKline Pharmaceuticals
What does Glaxosmithkline Pharmaceuticals Ltd do?
Where is Glaxosmithkline Pharmaceuticals Ltd (GLAXO) listed?
Which sector does Glaxosmithkline Pharmaceuticals Ltd belong to?
What is the market capitalisation of Glaxosmithkline Pharmaceuticals Ltd?
What is the PE ratio of Glaxosmithkline Pharmaceuticals Ltd?
What is the 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd?
Does Glaxosmithkline Pharmaceuticals Ltd pay dividends?
What is the Return on Equity (ROE) of Glaxosmithkline Pharmaceuticals Ltd?
Company Information
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GLAXO.md for Glaxosmithkline Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.